Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

By E. Ng, D. Shima, P. Calias, E. Cunningham, D. Guyer, A. Adamis. Nature reviews. Drug discovery, 2006

1,495 citations recorded by the source corpus.

Subfields: Molecular Biology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/122e7eb3ef8256d6582f50bb11d4faba1525087c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Adamis
2. N. Ferrara
3. Bo-Shiun Lai
4. M. Manoharan
5. Martin Egli
6. Menči Kunstelj
7. Vladka Gaberc Porekar
8. Huanhuan Chen

In Ophthalmology

1. N. Ferrara
2. A. Adamis

Citations in the corpus

• PEGylation of therapeutic proteins (2010, background): “Eight are PEGylated proteins and one [pegaptanib (Macugen® or Macuverse®)] is a PEGylated anti-vascular endothelial growth factor (VEGF) aptamer (an RNA oligonucleotide) for the treatment of ocular vascular disease [5].”
• Recent Advances in Aptamer Discovery and Applications (2019, background): “Pegaptanib blocks VEGF which plays a key role in pathological angiogenesis, for example, in ocular neovascular diseases, such as age-related macular degeneration (AMD) and diabetic macular oedema [157].”
• Current approaches in SELEX: An update to aptamer selection technology. (2015, background): “These retinopathies are accompanied by increased VEGF-based vascularization of the retina, causing blurry, myopia and blindness.”
• Chemistry, structure and function of approved oligonucleotide therapeutics (2023, background): “Vascular endothelial growth factor (VEGF) is a prominent drug target and extensive studies confirmed a role for VEGF in ocular neovascular diseases and demonstrated that VEGF165 is the isoform largely responsible for pathological ocular neovascularization (143).”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Consequently, pegaptanib (Macugen; Pfizer/Valeant) 17 and ranibizumab (Lucentis; Genentech/Novartis) 18 received FDA approval for neovascular age-related macular degeneration (AMD) in 2004 Identification of PlGF, the first VEGFA-related gene 260 • Identification of RTKs VEGFR1 (REF.”
• Aptamers come of age – at last (2006, background): “However, last year the first aptamer-based therapeutic agent (Macugen) for treating a form of macular degeneration entered clinical us”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Pegaptanib (Macugen) is a 50 kDa VEGF-A targeted RNA aptamer, which has been approved for angiogenic agerelated macular degeneration in December 2004, leading to good tolerability and negligible local adverse effects of AMD patients through intravitreous injections (Table 1).(390)”
• Aptamers as therapeutics (2010, background): “Initially, aptamers targeted to VEGf found utility in the treatment of wet macular degeneration 12 , in part because they had long half-lives in the ocular compartment.”